logo

For the Inventor, By the Inventor

Seoul, South Korea

Abclon Inc.


USPTO Granted Patents = 11



Forward Citations = 7

Loading Chart...
Loading Chart...

22 inventors (with patents filed for the assignee):

goldMedal Jong Seo Lee (7 out of 52 patents)

silverMedal Bong Kook Ko (6 out of 10 patents)

bronzeMedal Ki Hyun Kim (6 out of 51 patents)

4.  Kyu Tae Kim (6 out of 16 patents)

5.  Jong-Seo Lee (3 out of 23 patents)

6.  Hyun-Jong Lee (2 out of 2 patents)

7.  In Sik Hwang (1 out of 5 patents)

8.  Marco Ruella (1 out of 16 patents)

9.  Fredrik Frejd (1 out of 12 patents)

10.  Lindvi Gudmundsdotter (1 out of 4 patents)

11.  Kyu-Tae Kim (1 out of 2 patents)

12.  Young-Ha Lee (1 out of 1 patent)

13.  Sook-Yeon Lee (1 out of 1 patent)

14.  In-Sik Hwang (1 out of 1 patent)

15.  Bong-Kook Ko (1 out of 2 patents)


11 patents:

1. 12668640 - ANTI-CD30 ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR COMPRISING THEREOF (2026-06-30),
2. 12624099 - POLYPEPTIDE IMPROVED IN PROTEIN PURITY AND AFFINITY FOR ANTIGEN, CONJUGATE THEREOF WITH ANTIBODY OR ANTIGEN-BINDING FRAGMENT, AND PREPARATION METHOD THEREFOR (2026-05-12),
3. 12414998 - Anti-HER2 affibody and switchable chimeric antigen receptor using same as switch molecule (2025-09-16),
4. 12090171 - Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same and use thereof (2024-09-17),
5. 11945878 - Switch molecule and switchable chimeric antigen receptor (2024-04-02),
6. 11708409 - Antibody or antigen-binding fragment thereof that specifically recognizes B cell malignancies, chimeric antigen receptor comprising same, and uses thereof (2023-07-25),
7. 11534462 - Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same and use thereof (2022-12-27),
8. 11248059 - Antibody having improved stability and specifically binding to HER2 (2022-02-15),
9. 10633423 - IL-6-binding polypeptide complex (2020-04-28),
10. 10465008 - Antibodies against vascular endothelial growth factor receptor 2 (VEGFR2), encoding nucleic acid molecules and methods for treating an angiogenesis-related disease (2019-11-05),
11. 10174116 - Antibody specifically binding to HER2 (2019-01-08),
Company Overview
Abclon Inc. is a biotechnology company based in Seoul, South Korea, specializing in the development of innovative therapeutic solutions. The organization focuses on advancing antibody-based treatments and employs cutting-edge research in immunology and molecular biology. Abclon is dedicated to addressing unmet medical needs through its proprietary technologies, aiming to enhance patient outcomes in various disease areas. The company is committed to fostering collaboration and innovation within the global biotech landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

11 Patents

#371 in Seoul

#1,009 in South Korea

#51,714 in the World

Seoul, KR
Seoul, South Korea

Abclon Inc.

Forward Citations = 7

22 inventors:

goldMedal Jong Seo Lee (7 out of 52 patents)

silverMedal Bong Kook Ko (6 out of 10 patents)

bronzeMedal Ki Hyun Kim (6 out of 51 patents)

4.  Kyu Tae Kim (6 out of 16 patents)

5.  Jong-Seo Lee (3 out of 23 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abclon Inc.. Retrieved from https://idiyas.com/company/abclon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…